FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017377922> ?p ?o ?g. }

• W2017377922 endingPage "1019" @default.
• W2017377922 startingPage "1010" @default.
• W2017377922 abstract "In the United States, lung cancer represents the third most common cancer, causing the most cancer-related deaths, with treatment advances minimally affecting 5-year survivals. Erb-B family receptor elevations are found in many non-small cell lung cancer tumors, making this receptor family a drug target with potential for improving survival.Chemotherapy-naive patients with advanced non-small cell lung cancer were enrolled who had at least one elevated tumor-expressed member of the erb-B family receptors. This dose-finding, multicenter, open-label, phase I study combined chemotherapy with paclitaxel and carboplatin, adding the tyrosine kinase inhibitor CI-1033. Patients were evaluated for toxicity, response, survival, and pharmacokinetics.All 39 patients enrolled were assessable for safety and efficacy. Dose-limiting toxicities (diarrhea, rash, asthenia, and hypotension) occurred at the 200- and 150-mg dose levels of CI-1033; the maximum tolerated dose was 100 mg. Most toxicities were mild to moderate. Pharmacokinetics studies showed that paclitaxel levels were unaffected by CI-1033 and that CI-1033 plasma concentrations were consistent with historical controls. Ten patients (25.6%) achieved partial responses and another 11 (28.2%) had stable disease. In the recommended phase II dose cohort (n = 23), six patients (26%) had partial responses and six (26%) had stable disease. Median survival time was 12.4 months; median progression-free survival was 5.1 months.Paclitaxel-carboplatin, combined with CI-1033 at 100 mg/day, was safe and well tolerated. Efficacy and survival results were comparable to those of similar studies in advanced non-small cell lung cancer and therefore warrant additional phase II testing." @default.
• W2017377922 created "2016-06-24" @default.
• W2017377922 creator A5001166747 @default.
• W2017377922 creator A5023878438 @default.
• W2017377922 creator A5039144013 @default.
• W2017377922 creator A5045382891 @default.
• W2017377922 creator A5045668242 @default.
• W2017377922 creator A5046992109 @default.
• W2017377922 creator A5054504687 @default.
• W2017377922 creator A5057361837 @default.
• W2017377922 creator A5080538468 @default.
• W2017377922 creator A5091345764 @default.
• W2017377922 date "2006-11-01" @default.
• W2017377922 modified "2023-10-17" @default.
• W2017377922 title "A Phase I Evaluation of Oral CI-1033 in Combination with Paclitaxel and Carboplatin as First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer" @default.
• W2017377922 cites W1931708823 @default.
• W2017377922 cites W1967827870 @default.
• W2017377922 cites W1976565907 @default.
• W2017377922 cites W1979300931 @default.
• W2017377922 cites W1999015953 @default.
• W2017377922 cites W2002937040 @default.
• W2017377922 cites W2010397777 @default.
• W2017377922 cites W2014956732 @default.
• W2017377922 cites W2023389550 @default.
• W2017377922 cites W2029492857 @default.
• W2017377922 cites W2034269086 @default.
• W2017377922 cites W2043696829 @default.
• W2017377922 cites W2051120695 @default.
• W2017377922 cites W2075962843 @default.
• W2017377922 cites W2079959732 @default.
• W2017377922 cites W2116991201 @default.
• W2017377922 cites W2121046399 @default.
• W2017377922 cites W2122979735 @default.
• W2017377922 cites W2127101185 @default.
• W2017377922 cites W2138297714 @default.
• W2017377922 cites W2139248078 @default.
• W2017377922 cites W2139819066 @default.
• W2017377922 cites W2141937666 @default.
• W2017377922 cites W2142850084 @default.
• W2017377922 cites W2147037760 @default.
• W2017377922 cites W2150059798 @default.
• W2017377922 cites W2152419134 @default.
• W2017377922 cites W2153477391 @default.
• W2017377922 cites W2157013824 @default.
• W2017377922 cites W2162724777 @default.
• W2017377922 cites W2163707745 @default.
• W2017377922 cites W2169816570 @default.
• W2017377922 cites W2170329700 @default.
• W2017377922 cites W2280283394 @default.
• W2017377922 cites W3041047318 @default.
• W2017377922 doi "https://doi.org/10.1016/s1556-0864(15)31635-x" @default.
• W2017377922 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17409987" @default.
• W2017377922 hasPublicationYear "2006" @default.
• W2017377922 type Work @default.
• W2017377922 sameAs 2017377922 @default.
• W2017377922 citedByCount "6" @default.
• W2017377922 countsByYear W20173779222013 @default.
• W2017377922 countsByYear W20173779222014 @default.
• W2017377922 countsByYear W20173779222015 @default.
• W2017377922 countsByYear W20173779222019 @default.
• W2017377922 crossrefType "journal-article" @default.
• W2017377922 hasAuthorship W2017377922A5001166747 @default.
• W2017377922 hasAuthorship W2017377922A5023878438 @default.
• W2017377922 hasAuthorship W2017377922A5039144013 @default.
• W2017377922 hasAuthorship W2017377922A5045382891 @default.
• W2017377922 hasAuthorship W2017377922A5045668242 @default.
• W2017377922 hasAuthorship W2017377922A5046992109 @default.
• W2017377922 hasAuthorship W2017377922A5054504687 @default.
• W2017377922 hasAuthorship W2017377922A5057361837 @default.
• W2017377922 hasAuthorship W2017377922A5080538468 @default.
• W2017377922 hasAuthorship W2017377922A5091345764 @default.
• W2017377922 hasBestOaLocation W20173779221 @default.
• W2017377922 hasConcept C112705442 @default.
• W2017377922 hasConcept C121608353 @default.
• W2017377922 hasConcept C126322002 @default.
• W2017377922 hasConcept C143998085 @default.
• W2017377922 hasConcept C2776256026 @default.
• W2017377922 hasConcept C2776694085 @default.
• W2017377922 hasConcept C2777292972 @default.
• W2017377922 hasConcept C2778239845 @default.
• W2017377922 hasConcept C2781451048 @default.
• W2017377922 hasConcept C71924100 @default.
• W2017377922 hasConcept C90924648 @default.
• W2017377922 hasConceptScore W2017377922C112705442 @default.
• W2017377922 hasConceptScore W2017377922C121608353 @default.
• W2017377922 hasConceptScore W2017377922C126322002 @default.
• W2017377922 hasConceptScore W2017377922C143998085 @default.
• W2017377922 hasConceptScore W2017377922C2776256026 @default.
• W2017377922 hasConceptScore W2017377922C2776694085 @default.
• W2017377922 hasConceptScore W2017377922C2777292972 @default.
• W2017377922 hasConceptScore W2017377922C2778239845 @default.
• W2017377922 hasConceptScore W2017377922C2781451048 @default.
• W2017377922 hasConceptScore W2017377922C71924100 @default.
• W2017377922 hasConceptScore W2017377922C90924648 @default.
• W2017377922 hasIssue "9" @default.
• W2017377922 hasLocation W20173779221 @default.
• W2017377922 hasLocation W20173779222 @default.
• W2017377922 hasOpenAccess W2017377922 @default.

• next